TapewireFind a company

person · Reporting owner

Young Richard A

Disclosed activity across 3 companies

Tapewire entity
26224
SEC CIK
0001490283

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
Camp4 Therapeutics CorpCAMP · Entity 1161DirectorAugust 03, 2026August 05, 2026
Omega Therapeutics, Inc.OMGA · Entity 83618DirectorJune 20, 2024June 21, 2024
Syros Pharmaceuticals, Inc.SYRS · Entity 85437DirectorSeptember 16, 2024September 18, 2024

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Camp4 Therapeutics Corp

Report date August 03, 2026 · Filed August 05, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect186,388 Reported balance After 2026-08-03 transaction · row 1
1 source row

Row 1 · 2026-08-03 · Purchase · Acquired 16,378 · Balance 186,388

F1: On August 3, 2026, the reporting person acquired shares in the second closing of a private placement by the Issuer pursuant to the terms of a Securities Purchase Agreement, dated as of September 9, 2025, as amended on August 3, 2026, by and among the Issuer and certain institutional investors and certain directors, employees, and consultants, at a purchase price of $1.65 per share.

Filing footnotes · ownership attribution and instrument terms

F1: On August 3, 2026, the reporting person acquired shares in the second closing of a private placement by the Issuer pursuant to the terms of a Securities Purchase Agreement, dated as of September 9, 2025, as amended on August 3, 2026, by and among the Issuer and certain institutional investors and certain directors, employees, and consultants, at a purchase price of $1.65 per share.

Omega Therapeutics, Inc.

Report date June 20, 2024 · Filed June 21, 2024

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.20 · Expires 2034-06-19Direct25,000 Reported balance After 2024-06-20 transaction · row 1 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 1 · 2024-06-20 · Grant · Acquired 25,000 · Balance 25,000

F1: The options vest and become exercisable on the earlier of (i) the date of the Issuer's next annual meeting of stockholders and (ii) the first anniversary of the date of grant, subject to the Reporting Person's continued service on the Issuer's Board of Directors through such vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: The options vest and become exercisable on the earlier of (i) the date of the Issuer's next annual meeting of stockholders and (ii) the first anniversary of the date of grant, subject to the Reporting Person's continued service on the Issuer's Board of Directors through such vesting date.

Syros Pharmaceuticals, Inc.

Report date September 16, 2024 · Filed September 18, 2024

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect10,667 Reported balance After 2024-09-16 transaction · row 1
1 source row

Row 1 · 2024-09-16 · Exercise / conversion · Acquired 2,667 · Balance 10,667

F1: Represents shares of common stock received upon vesting of a restricted stock unit ("RSU") award

Restricted Stock UnitsSEC Table II · derivative / convertible securityDirect2,667 Reported balance After 2024-09-16 transaction · row 2 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 2 · 2024-09-16 · Exercise / conversion · Disposed 2,667 · Balance 2,667

F2: Each RSU represents the contingent right to receive one share of the issuer's common stock.

F3: Represents a restricted stock unit award granted on September 16, 2022. These restricted stock units vest in three equal annual installments commencing on September 16, 2023.

Filing footnotes · ownership attribution and instrument terms

F1: Represents shares of common stock received upon vesting of a restricted stock unit ("RSU") award

F2: Each RSU represents the contingent right to receive one share of the issuer's common stock.

F3: Represents a restricted stock unit award granted on September 16, 2022. These restricted stock units vest in three equal annual installments commencing on September 16, 2023.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
August 03, 2026 Filed Aug 5, 2026 21:09 UTC Camp4 Therapeutics Corp CAMP · Entity 1161 PurchaseCommon Stock 16,378 $1.65 $27,023.70
Disclosure

SEC source: 0001628280-26-053513 · wk-form4_1785964164.xml · nonDerivative · entry 1

Young Richard A · CIK 0001490283 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 186,388

F1 · price: On August 3, 2026, the reporting person acquired shares in the second closing of a private placement by the Issuer pursuant to the terms of a Securities Purchase Agreement, dated as of September 9, 2025, as amended on August 3, 2026, by and among the Issuer and certain institutional investors and certain directors, employees, and consultants, at a purchase price of $1.65 per share.

Read SEC document
June 10, 2026 Filed Jun 12, 2026 20:16 UTC Camp4 Therapeutics Corp CAMP · Entity 1161 GrantStock Option (Right to Buy) · Derivative 28,000 $0.00 Strike: $4.34 $0.00
Disclosure

SEC source: 0001628280-26-042862 · wk-form4_1781295368.xml · derivative · entry 1

Young Richard A · CIK 0001490283 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 28,000

Underlying: Common Stock · 28,000 shares

Expires 2036-06-09

F1 · derivative.exercise_date: The shares underlying the option vest in their entirety on the earlier of the first anniversary of the grant date or the date of the issuer's next annual meeting of stockholders, subject to continued service to the Company through the applicable vesting date.

Read SEC document
September 11, 2025 Filed Sep 11, 2025 20:22 UTC Camp4 Therapeutics Corp CAMP · Entity 1161 PurchaseCommon Stock 15,151 $1.65 $24,999.15
Disclosure

SEC source: 0001490283-25-000003 · wk-form4_1757622149.xml · nonDerivative · entry 1

Young Richard A · CIK 0001490283 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 170,010

F1 · price: On September 11, 2025, the reporting person acquired shares in a private placement by the Issuer pursuant to the terms of a Securities Purchase Agreement, dated as of September 9, 2025, by and among the Issuer and certain institutional investors and certain directors, employees, and consultants, at a purchase price of $1.65 per share.

Read SEC document
June 25, 2025 Filed Jun 27, 2025 20:03 UTC Camp4 Therapeutics Corp CAMP · Entity 1161 GrantStock Option (Right to Buy) · Derivative 9,000 $0.00 Strike: $1.56 $0.00
Disclosure

SEC source: 0001736730-25-000060 · wk-form4_1751054585.xml · derivative · entry 1

Young Richard A · CIK 0001490283 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 9,000

Underlying: Common Stock · 9,000 shares

Expires 2035-06-24

F1 · derivative.exercise_date: The shares underlying the option vest in their entirety on the earlier of the first anniversary of the grant date or the date of the issuer's next annual meeting of stockholders, subject to continued service to the issuer's board of directors through the applicable vesting date.

Read SEC document
October 15, 2024 Filed Oct 15, 2024 21:46 UTC Camp4 Therapeutics Corp CAMP · Entity 1161 ConversionSeries A Prime Preferred Stock · Derivative 100,014 Not disclosed Not disclosed
Disclosure

SEC source: 0001104659-24-108700 · tm2426125-2_4seq1.xml · derivative · entry 2

Young Richard A · CIK 0001490283 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 8,917 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: On October 15, 2024, the shares of Series A Prime Convertible Preferred Stock automatically converted into shares of Common Stock on a 11.2158-for-1 basis without payment of further consideration upon the closing of the Issuer's initial public offering.

F1 · price: On October 15, 2024, the shares of Series A Prime Convertible Preferred Stock automatically converted into shares of Common Stock on a 11.2158-for-1 basis without payment of further consideration upon the closing of the Issuer's initial public offering.

F1 · derivative.exercise_date: On October 15, 2024, the shares of Series A Prime Convertible Preferred Stock automatically converted into shares of Common Stock on a 11.2158-for-1 basis without payment of further consideration upon the closing of the Issuer's initial public offering.

F1 · derivative.expiration_date: On October 15, 2024, the shares of Series A Prime Convertible Preferred Stock automatically converted into shares of Common Stock on a 11.2158-for-1 basis without payment of further consideration upon the closing of the Issuer's initial public offering.

Read SEC document
October 15, 2024 Filed Oct 15, 2024 21:46 UTC Camp4 Therapeutics Corp CAMP · Entity 1161 ConversionCommon Stock 8,917 Not disclosed Not disclosed
Disclosure

SEC source: 0001104659-24-108700 · tm2426125-2_4seq1.xml · nonDerivative · entry 1

Young Richard A · CIK 0001490283 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 154,859

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: On October 15, 2024, the shares of Series A Prime Convertible Preferred Stock automatically converted into shares of Common Stock on a 11.2158-for-1 basis without payment of further consideration upon the closing of the Issuer's initial public offering.

F1 · price: On October 15, 2024, the shares of Series A Prime Convertible Preferred Stock automatically converted into shares of Common Stock on a 11.2158-for-1 basis without payment of further consideration upon the closing of the Issuer's initial public offering.

Read SEC document
September 16, 2024 Filed Sep 18, 2024 21:00 UTC Syros Pharmaceuticals, Inc. SYRS · Entity 85437 Exercise / conversionRestricted Stock Units · Derivative 2,667 $0.00 $0.00
Disclosure

SEC source: 0000950170-24-107862 · ownership.xml · derivative · entry 2

Young Richard A · CIK 0001490283 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,667

Underlying: Common Stock · 2,667 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each RSU represents the contingent right to receive one share of the issuer's common stock.

F3 · derivative.exercise_date: Represents a restricted stock unit award granted on September 16, 2022. These restricted stock units vest in three equal annual installments commencing on September 16, 2023.

F3 · derivative.expiration_date: Represents a restricted stock unit award granted on September 16, 2022. These restricted stock units vest in three equal annual installments commencing on September 16, 2023.

Read SEC document
September 16, 2024 Filed Sep 18, 2024 21:00 UTC Syros Pharmaceuticals, Inc. SYRS · Entity 85437 Exercise / conversionCommon Stock 2,667 Not disclosed Not disclosed
Disclosure

SEC source: 0000950170-24-107862 · ownership.xml · nonDerivative · entry 1

Young Richard A · CIK 0001490283 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,667

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Represents shares of common stock received upon vesting of a restricted stock unit ("RSU") award

Read SEC document
June 28, 2024 Filed Jul 2, 2024 20:15 UTC Syros Pharmaceuticals, Inc. SYRS · Entity 85437 SaleCommon Stock 34,837 $5.12 $178,365.44
Disclosure

SEC source: 0000950170-24-080480 · ownership.xml · nonDerivative · entry 1

Young Richard A · CIK 0001490283 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 8,000

F1 · kind: The sale reported on this Form 4 was effected pursuant to a trading plan adopted on March 29, 2024 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.

Read SEC document
June 20, 2024 Filed Jun 21, 2024 16:20 UTC Omega Therapeutics, Inc. OMGA · Entity 83618 GrantStock Option (Right to Buy) · Derivative 25,000 $0.00 Strike: $2.20 $0.00
Disclosure

SEC source: 0000950170-24-076262 · ownership.xml · derivative · entry 1

Young Richard A · CIK 0001490283 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 25,000

Underlying: Common Stock · 25,000 shares

Expires 2034-06-19

F1 · derivative.exercise_date: The options vest and become exercisable on the earlier of (i) the date of the Issuer's next annual meeting of stockholders and (ii) the first anniversary of the date of grant, subject to the Reporting Person's continued service on the Issuer's Board of Directors through such vesting date.

Read SEC document
June 05, 2024 Filed Jun 7, 2024 20:30 UTC Syros Pharmaceuticals, Inc. SYRS · Entity 85437 GrantStock Option (right to buy) · Derivative 6,000 $0.00 Strike: $5.30 $0.00
Disclosure

SEC source: 0000950170-24-070705 · ownership.xml · derivative · entry 2

Young Richard A · CIK 0001490283 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,000

Underlying: Common Stock · 6,000 shares

Expires 2034-06-04

F1 · derivative.exercise_date: The option becomes exercisable as to 50% of the shares underlying the award on the six month anniversary of the date of grant, with the remainder vesting in equal monthly installments of 8.33% of the shares underlying the award until the first anniversary of the date of grant, subject to the reporting person's continued service as a director through each applicable vesting date.

Read SEC document
June 05, 2024 Filed Jun 7, 2024 20:30 UTC Syros Pharmaceuticals, Inc. SYRS · Entity 85437 GrantCommon Stock 4,000 $0.00 $0.00
Disclosure

SEC source: 0000950170-24-070705 · ownership.xml · nonDerivative · entry 1

Young Richard A · CIK 0001490283 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 42,837

Read SEC document
September 16, 2023 Filed Sep 19, 2023 20:48 UTC Syros Pharmaceuticals, Inc. SYRS · Entity 85437 Exercise / conversionRestricted Stock Units · Derivative 2,666 $0.00 $0.00
Disclosure

SEC source: 0001209191-23-049978 · doc4.xml · derivative · entry 2

Young Richard A · CIK 0001490283 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,334

Underlying: Common Stock · 2,666 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents the contingent right to receive one share of the issuer's common stock.

F3 · derivative.exercise_date: Represents a restricted stock unit award granted on September 16, 2022. These restricted stock units vest in three equal annual installments commencing on September 16, 2023.

F3 · derivative.expiration_date: Represents a restricted stock unit award granted on September 16, 2022. These restricted stock units vest in three equal annual installments commencing on September 16, 2023.

Read SEC document
September 16, 2023 Filed Sep 19, 2023 20:48 UTC Syros Pharmaceuticals, Inc. SYRS · Entity 85437 Exercise / conversionCommon Stock 2,666 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-23-049978 · doc4.xml · nonDerivative · entry 1

Young Richard A · CIK 0001490283 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 38,837

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: Represents shares of common stock received upon vesting of a restricted stock unit award.

F1 · price: Represents shares of common stock received upon vesting of a restricted stock unit award.

Read SEC document
June 07, 2023 Filed Jun 9, 2023 16:05 UTC Omega Therapeutics, Inc. OMGA · Entity 83618 GrantStock Option (Right to Buy) · Derivative 18,118 $0.00 Strike: $8.39 $0.00
Disclosure

SEC source: 0000899243-23-015153 · doc4.xml · derivative · entry 1

Young Richard A · CIK 0001490283 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 18,118

Underlying: Common Stock · 18,118 shares

Expires 2033-06-06

F1 · derivative.exercise_date: The options vest and become exercisable on the earlier of (i) the date of the Issuer's next annual meeting of stockholders and (ii) the first anniversary of the date of grant, subject to the Reporting Person's continued service on the Issuer's Board of Directors through such vesting date.

Read SEC document
June 02, 2023 Filed Jun 5, 2023 16:15 UTC Omega Therapeutics, Inc. OMGA · Entity 83618 SaleCommon Stock 5,000 $8.00 $40,000.00
Disclosure

SEC source: 0000899243-23-014449 · doc4.xml · nonDerivative · entry 1

Young Richard A · CIK 0001490283 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 739,118

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 31, 2022.

Read SEC document
June 01, 2023 Filed Jun 2, 2023 20:27 UTC Syros Pharmaceuticals, Inc. SYRS · Entity 85437 GrantStock Option (right to buy) · Derivative 6,000 $0.00 Strike: $3.70 $0.00
Disclosure

SEC source: 0001209191-23-033738 · doc4.xml · derivative · entry 2

Young Richard A · CIK 0001490283 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,000

Underlying: Common Stock · 6,000 shares

Expires 2033-05-31

F2 · derivative.exercise_date: The option becomes exercisable as to 50% of the shares underlying the award on the six month anniversary of the date of grant, with the remainder vesting in equal monthly installments of 8.33% of the shares underlying the award until the first anniversary of the date of grant, subject to the reporting person's continued service as a director through each applicable vesting date.

Read SEC document
June 01, 2023 Filed Jun 2, 2023 20:27 UTC Syros Pharmaceuticals, Inc. SYRS · Entity 85437 GrantCommon Stock 4,000 $0.00 $0.00
Disclosure

SEC source: 0001209191-23-033738 · doc4.xml · nonDerivative · entry 1

Young Richard A · CIK 0001490283 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 36,171

F1 · balance_after: The amount of securities beneficially owned following the transaction reported in this Form 4 reflects the 1-for-10 reverse stock split effected by the issuer on September 16, 2022.

Read SEC document
May 01, 2023 Filed May 3, 2023 16:05 UTC Omega Therapeutics, Inc. OMGA · Entity 83618 SaleCommon Stock 5,000 $8.00 $40,000.00
Disclosure

SEC source: 0000899243-23-012077 · doc4.xml · nonDerivative · entry 1

Young Richard A · CIK 0001490283 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 744,118

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 31, 2022.

Read SEC document
April 06, 2023 Filed Apr 10, 2023 16:05 UTC Omega Therapeutics, Inc. OMGA · Entity 83618 SaleCommon Stock 5,000 $8.00 $40,000.00
Disclosure

SEC source: 0000899243-23-011034 · doc4.xml · nonDerivative · entry 1

Young Richard A · CIK 0001490283 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 749,118

F1 · kind: The sales reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 31, 2022.

Read SEC document
March 17, 2023 Filed Mar 20, 2023 16:05 UTC Omega Therapeutics, Inc. OMGA · Entity 83618 SaleCommon Stock 10,000 $8.00 $80,000.00
Disclosure

SEC source: 0000899243-23-009094 · doc4.xml · nonDerivative · entry 1

Young Richard A · CIK 0001490283 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 754,118

F1 · kind: The sales reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 31, 2022.

Read SEC document
January 10, 2023 Filed Jan 11, 2023 16:14 UTC Omega Therapeutics, Inc. OMGA · Entity 83618 SaleCommon Stock 20,000 $8.00 $160,000.00
Disclosure

SEC source: 0000899243-23-001594 · doc4.xml · nonDerivative · entry 1

Young Richard A · CIK 0001490283 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 764,118

F1 · kind: The sales reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 31, 2022.

Read SEC document
September 16, 2022 Filed Sep 19, 2022 21:16 UTC Syros Pharmaceuticals, Inc. SYRS · Entity 85437 GrantRestricted Stock Units · Derivative 8,000 $0.00 $0.00
Disclosure

SEC source: 0001209191-22-050562 · doc4.xml · derivative · entry 2

Young Richard A · CIK 0001490283 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,000

Underlying: Common Stock · 8,000 shares

Expires not disclosed

F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents the contingent right to receive one share of the issuer's common stock.

F3 · derivative.exercise_date: These RSUs will vest in three equal annual installments commencing on September 16, 2023. Amounts reported in this Form 4 reflect the 1-for-10 reverse stock split effected by the issuer on September 16, 2022.

F3 · derivative.expiration_date: These RSUs will vest in three equal annual installments commencing on September 16, 2023. Amounts reported in this Form 4 reflect the 1-for-10 reverse stock split effected by the issuer on September 16, 2022.

Read SEC document
September 16, 2022 Filed Sep 19, 2022 21:16 UTC Syros Pharmaceuticals, Inc. SYRS · Entity 85437 GrantStock Option (right to buy) · Derivative 12,000 $0.00 Strike: $7.35 $0.00
Disclosure

SEC source: 0001209191-22-050562 · doc4.xml · derivative · entry 1

Young Richard A · CIK 0001490283 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,000

Underlying: Common Stock · 12,000 shares

Expires 2032-09-15

F1 · derivative.exercise_date: The option becomes exercisable as to 16.66% of the shares underlying the award on the six month anniversary of the date of grant, with the remainder vesting in equal monthly installments until the third anniversary of the date of grant, subject to the reporting person's continued service as a director through each applicable vesting date. Amounts reported in this Form 4 reflect the 1-for-10 reverse stock split effected by the issuer on September 16, 2022.

Read SEC document
September 14, 2022 Filed Sep 15, 2022 16:10 UTC Omega Therapeutics, Inc. OMGA · Entity 83618 SaleCommon Stock 10,000 $8.00 $80,000.00
Disclosure

SEC source: 0000899243-22-031138 · doc4.xml · nonDerivative · entry 1

Young Richard A · CIK 0001490283 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 784,118

F1 · kind: The sales reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.

Read SEC document
June 08, 2022 Filed Jun 10, 2022 16:10 UTC Omega Therapeutics, Inc. OMGA · Entity 83618 GrantOption (Right to Buy) · Derivative 18,118 $0.00 Strike: $3.31 $0.00
Disclosure

SEC source: 0000899243-22-021892 · doc4.xml · derivative · entry 1

Young Richard A · CIK 0001490283 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,118

Underlying: Common Stock · 18,118 shares

Expires 2032-06-07

F1 · derivative.exercise_date: The options vest and become exercisable on the earlier of (i) the date of the Issuer's next annual meeting of stockholders and (ii) the first anniversary of the date of grant, subject to the Reporting Person's continued service on the Issuer's Board of Directors through such vesting date.

Read SEC document
June 01, 2022 Filed Jun 2, 2022 23:09 UTC Syros Pharmaceuticals, Inc. SYRS · Entity 85437 GrantStock Option (right to buy) · Derivative 17,500 $0.00 Strike: $0.78 $0.00
Disclosure

SEC source: 0001209191-22-033714 · doc4.xml · derivative · entry 1

Young Richard A · CIK 0001490283 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,500

Underlying: Common Stock · 17,500 shares

Expires 2032-05-31

F1 · derivative.exercise_date: The option becomes exercisable as to 50% of the shares underlying the award on the six month anniversary of the date of grant, with the remainder vesting in equal monthly installments until the first anniversary of the date of grant, subject to the reporting person's continued service as a director through each applicable vesting date.

Read SEC document
June 08, 2021 Filed Jun 10, 2021 21:31 UTC Syros Pharmaceuticals, Inc. SYRS · Entity 85437 GrantStock Option (right to buy) · Derivative 17,500 $0.00 Strike: $6.30 $0.00
Disclosure

SEC source: 0001209191-21-039580 · doc4.xml · derivative · entry 1

Young Richard A · CIK 0001490283 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,500

Underlying: Common Stock · 17,500 shares

Expires 2031-06-07

F1 · derivative.exercise_date: The option becomes exercisable as to 50% of the shares underlying the award on the six month anniversary of the date of grant, with the remainder vesting in equal monthly installments until the first anniversary of the date of grant, subject to the reporting person's continued service as a director through each applicable vesting date.

Read SEC document
February 16, 2021 Filed Feb 18, 2021 22:34 UTC Syros Pharmaceuticals, Inc. SYRS · Entity 85437 SaleCommon Stock 3,750 $12.05 $45,187.50
Disclosure

SEC source: 0001209191-21-011992 · doc4.xml · nonDerivative · entry 1

Young Richard A · CIK 0001490283 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 321,711

F1 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.75 to $12.415, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

Read SEC document
February 08, 2021 Filed Feb 10, 2021 22:29 UTC Syros Pharmaceuticals, Inc. SYRS · Entity 85437 SaleCommon Stock 3,750 $13.04 $48,900.00
Disclosure

SEC source: 0001209191-21-009341 · doc4.xml · nonDerivative · entry 1

Young Richard A · CIK 0001490283 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 325,461

F1 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.69 to $13.30, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

Read SEC document
November 17, 2020 Filed Nov 18, 2020 21:33 UTC Syros Pharmaceuticals, Inc. SYRS · Entity 85437 SaleCommon Stock 5,357 $8.75 $46,873.75
Disclosure

SEC source: 0001209191-20-059113 · doc4.xml · nonDerivative · entry 2

Young Richard A · CIK 0001490283 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 339,211

F1 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.

Read SEC document
November 17, 2020 Filed Feb 10, 2021 22:28 UTC Amendment Syros Pharmaceuticals, Inc. SYRS · Entity 85437 SaleCommon Stock 5,357 $8.75 $46,873.75
Disclosure

SEC source: 0001209191-21-009339 · doc4a.xml · nonDerivative · entry 2

Young Richard A · CIK 0001490283 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 329,211

F1 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.

F3 · balance_after: This amendment to the Statement of Changes in Beneficial Ownership of Securities is being filed to correct a typographical error in Column 5 regarding the amount of securities beneficially owned by the reporting person following the reported transactions.

Read SEC document
November 16, 2020 Filed Nov 18, 2020 21:33 UTC Syros Pharmaceuticals, Inc. SYRS · Entity 85437 SaleCommon Stock 633 $8.98 $5,684.34
Disclosure

SEC source: 0001209191-20-059113 · doc4.xml · nonDerivative · entry 1

Young Richard A · CIK 0001490283 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 344,568

F1 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.93 to $9.01, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

Read SEC document
November 16, 2020 Filed Feb 10, 2021 22:28 UTC Amendment Syros Pharmaceuticals, Inc. SYRS · Entity 85437 SaleCommon Stock 633 $8.98 $5,684.34
Disclosure

SEC source: 0001209191-21-009339 · doc4a.xml · nonDerivative · entry 1

Young Richard A · CIK 0001490283 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 334,568

F1 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.93 to $9.01, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

F3 · balance_after: This amendment to the Statement of Changes in Beneficial Ownership of Securities is being filed to correct a typographical error in Column 5 regarding the amount of securities beneficially owned by the reporting person following the reported transactions.

Read SEC document
October 19, 2020 Filed Oct 19, 2020 22:36 UTC Syros Pharmaceuticals, Inc. SYRS · Entity 85437 SaleCommon Stock 5,673 $8.75 $49,638.75
Disclosure

SEC source: 0001209191-20-055334 · doc4.xml · nonDerivative · entry 1

Young Richard A · CIK 0001490283 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 335,201

F1 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.

Read SEC document
October 15, 2020 Filed Oct 16, 2020 20:39 UTC Syros Pharmaceuticals, Inc. SYRS · Entity 85437 SaleCommon Stock 317 $8.75 $2,773.75
Disclosure

SEC source: 0001209191-20-055059 · doc4.xml · nonDerivative · entry 1

Young Richard A · CIK 0001490283 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 340,874

F1 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.75 to $8.82, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

Read SEC document
September 15, 2020 Filed Sep 16, 2020 12:32 UTC Syros Pharmaceuticals, Inc. SYRS · Entity 85437 SaleCommon Stock 5,990 $10.39 $62,236.10
Disclosure

SEC source: 0001209191-20-050618 · doc4.xml · nonDerivative · entry 1

Young Richard A · CIK 0001490283 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 341,191

F1 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.03 to $10.63, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

Read SEC document
August 17, 2020 Filed Aug 19, 2020 20:33 UTC Syros Pharmaceuticals, Inc. SYRS · Entity 85437 SaleCommon Stock 5,990 $12.59 $75,414.10
Disclosure

SEC source: 0001209191-20-047501 · doc4.xml · nonDerivative · entry 1

Young Richard A · CIK 0001490283 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 347,181

F1 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.90 to $12.99, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

Read SEC document
July 15, 2020 Filed Jul 17, 2020 20:11 UTC Syros Pharmaceuticals, Inc. SYRS · Entity 85437 SaleCommon Stock 5,990 $11.85 $70,981.50
Disclosure

SEC source: 0001209191-20-042796 · doc4.xml · nonDerivative · entry 1

Young Richard A · CIK 0001490283 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 353,171

F1 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.39 to $12.19, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

Read SEC document
June 15, 2020 Filed Jun 16, 2020 20:53 UTC Syros Pharmaceuticals, Inc. SYRS · Entity 85437 SaleCommon Stock 5,990 $8.75 $52,412.50
Disclosure

SEC source: 0001209191-20-037001 · doc4.xml · nonDerivative · entry 1

Young Richard A · CIK 0001490283 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 359,161

F1 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.

Read SEC document
June 11, 2020 Filed Jun 11, 2020 20:54 UTC Syros Pharmaceuticals, Inc. SYRS · Entity 85437 GrantStock Option (right to buy) · Derivative 17,500 $0.00 Strike: $9.17 $0.00
Disclosure

SEC source: 0001209191-20-035971 · doc4.xml · derivative · entry 1

Young Richard A · CIK 0001490283 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,500

Underlying: Common Stock · 17,500 shares

Expires 2030-06-10

F1 · derivative.exercise_date: The option becomes exercisable as to 50% of the shares underlying the award on the six month anniversary of the date of grant, with the remainder vesting in equal monthly installments until the first anniversary of the date of grant, subject to the reporting person's continued service as a director through each applicable vesting date.

Read SEC document
May 15, 2020 Filed May 15, 2020 21:13 UTC Syros Pharmaceuticals, Inc. SYRS · Entity 85437 SaleCommon Stock 5,990 $9.22 $55,242.18
Disclosure

SEC source: 0001209191-20-029763 · doc4.xml · nonDerivative · entry 1

Young Richard A · CIK 0001490283 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 365,151

F1 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.78 to $9.55, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

Read SEC document
April 15, 2020 Filed Apr 17, 2020 20:02 UTC Syros Pharmaceuticals, Inc. SYRS · Entity 85437 SaleCommon Stock 23,960 $8.75 $209,650.00
Disclosure

SEC source: 0001209191-20-024775 · doc4.xml · nonDerivative · entry 1

Young Richard A · CIK 0001490283 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 371,141

F1 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.

Read SEC document
August 16, 2019 Filed Aug 19, 2019 20:08 UTC Syros Pharmaceuticals, Inc. SYRS · Entity 85437 SaleCommon Stock 22,700 $10.00 $227,000.00
Disclosure

SEC source: 0001209191-19-046516 · doc4.xml · nonDerivative · entry 2

Young Richard A · CIK 0001490283 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 395,101

F1 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.

Read SEC document
August 15, 2019 Filed Aug 19, 2019 20:08 UTC Syros Pharmaceuticals, Inc. SYRS · Entity 85437 SaleCommon Stock 2,300 $10.00 $23,000.00
Disclosure

SEC source: 0001209191-19-046516 · doc4.xml · nonDerivative · entry 1

Young Richard A · CIK 0001490283 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 417,801

F1 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.

Read SEC document
June 11, 2019 Filed Jun 12, 2019 20:18 UTC Syros Pharmaceuticals, Inc. SYRS · Entity 85437 GrantStock Option (right to buy) · Derivative 11,000 $0.00 Strike: $5.60 $0.00
Disclosure

SEC source: 0001209191-19-036369 · doc4.xml · derivative · entry 1

Young Richard A · CIK 0001490283 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,000

Underlying: Common Stock · 11,000 shares

Expires 2029-06-10

F1 · derivative.exercise_date: The option becomes exercisable as to 50% of the shares underlying the award on the six month anniversary of the date of grant, with the remainder vesting in equal monthly installments until the first anniversary of the date of grant, subject to the reporting person's continued service as a director through each applicable vesting date.

Read SEC document
June 14, 2018 Filed Jun 15, 2018 20:30 UTC Syros Pharmaceuticals, Inc. SYRS · Entity 85437 GrantStock Option (right to buy) · Derivative 11,000 $0.00 Strike: $12.95 $0.00
Disclosure

SEC source: 0001179110-18-008625 · edgar.xml · derivative · entry 1

Young Richard A · CIK 0001490283 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,000

Underlying: Common Stock · 11,000 shares

Expires 2028-06-13

F1 · derivative.exercise_date: The option becomes exercisable as to 50% of the shares underlying the award on the six month anniversary of the date of grant, with the remainder vesting in equal monthly installments until the first anniversary of the date of grant, subject to the reporting person's continued service as a director through each applicable vesting date.

Read SEC document
August 14, 2017 Filed Aug 16, 2017 20:08 UTC Syros Pharmaceuticals, Inc. SYRS · Entity 85437 SaleCommon Stock 3,282 $22.00 $72,204.00
Disclosure

SEC source: 0001104659-17-052251 · a4.xml · nonDerivative · entry 1

Young Richard A · CIK 0001490283 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 420,101

F1 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.

Read SEC document
July 25, 2017 Filed Jul 27, 2017 20:09 UTC Syros Pharmaceuticals, Inc. SYRS · Entity 85437 SaleCommon Stock 3,282 $22.09 $72,495.77
Disclosure

SEC source: 0001179110-17-010734 · edgar.xml · nonDerivative · entry 1

Young Richard A · CIK 0001490283 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 423,383

F1 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.00 to $22.43, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

Read SEC document
June 08, 2017 Filed Jun 12, 2017 20:02 UTC Syros Pharmaceuticals, Inc. SYRS · Entity 85437 GrantStock Option (right to buy) · Derivative 11,000 $0.00 Strike: $14.26 $0.00
Disclosure

SEC source: 0001179110-17-008894 · edgar.xml · derivative · entry 1

Young Richard A · CIK 0001490283 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,000

Underlying: Common Stock · 11,000 shares

Expires 2027-06-07

F1 · derivative.exercise_date: The option becomes exercisable as to 50% of the shares underlying the award on the six month anniversary of the award, with the remainder vesting in equal monthly installments until the first anniversary of the date of the award, subject to the reporting person's continued service as a director through each applicable vesting date.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.